Company profile
Intelligent Bio Solutions Inc.
NASDAQ: INBS · Healthcare · Medical - Devices
#750 of 1,418 Healthcare companies by revenue38th-percentile growth
EA Score
40DFH 37DQ 40GM 48SS 37
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, Piotroski F · ↓ return on equity, growth stability
Methodology →Revenue TTM
$3.9M
Rev growth YoY (TTM)
+33.3%
Net income (FY)
-$10.6M
Employees
54
as of 2026-08-25
Market cap
$1.6M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.1M$3.1M2025
Net income-$10.6M-$10.6M2025
Operating income-$10.6M-$10.6M2025
Total assets$8.2M$8.2M2025
Liabilities$5.4M$5.4M2025
Equity$3.0M$3.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Other Sales100%
By geography
Other Country67%
Asia Pacific21%
Americas11%
The read
What is Intelligent Bio Solutions Inc.’s revenue?
Intelligent Bio Solutions Inc. booked $3.1M in FY2025 revenue, contracting 1.9% year over year — slower than 62% of Healthcare companies we track, at a -346.2% net margin.
Peers · Healthcare
Dyadic International, Inc.39DPolarean Imaging plc——Numinus Wellness Inc.——Net Medical Xpress Solutions, Inc.——TherapeuticsMD, Inc.60CXenetic Biosciences, Inc.56CNeighbors
New York →Key facts
CEOHarry Simeonidis
SectorHealthcare
IndustryMedical - Devices
HeadquartersNew York City, NY
ExchangeNASDAQ: INBS
Employees54
IPO date2020-12-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.